Abstract
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Dr. Tinsley gives her perspective on encouraging results from the 5-year analysis of the MURANO study showing the benefit of fixed-duration venetoclax and rituximab. She evaluates early phase 1b/2 trial results showing the benefit of the ViPOR regimen but also associated adverse events that advanced practitioners (APs) should be aware of. Dr. Kurtin considers how APs can use the new Burkitt Lymphoma International Prognostic Index (BL-IPI) to discuss individual risk with patients and risk stratify them.
On the JADPRO website, you’ll find several short videos on these important abstracts that the faculty members filmed on site. Visit advancedpractitioner.com/highlights to continue the experience!
